Generalized versus localized vitiligo after ixekizumab: May previous treatment affect the clinical presentation?

Our experience in addition to that described by the authors seems to confirm that vitiligo is a rare adverse event due to anti-IL-17[[2], [4]]; nevertheless, the occurrence of de novo vitiligo is not a contraindication to treatment. Demographic and clinical characteristics of patients with both psoriasis and vitiligo in a cohort of vitiligo patients: a cross-sectional study. [Extracted from the article]